tidase IV (DPP-IV) and cathepsin G, respectively] and have modified chemotactic and antiviral functionality compared with that of intact RANTES (6, 7 ) . Furthermore, there is evidence that an O-linked glycosylated RANTES variant may exist (8 ) . Consequently, research concerned with RANTES, which was discovered in 1988 via a cDNA study of T cells (9 ) , has in a short amount of time begun to unravel a molecule of depth that appears to be connected to an array of pathophysiological conditions that arise in humans.
The clinical significance of RANTES is considerable, as it has been associated with many diseases including kidney-related complications (e.g., renal failure and renal cancer), autoimmune diseases (e.g., arthritis, diabetes, and glomerulonephritis), sepsisinduced disseminated intravascular coagulation in infants, and several forms of carcinoma including breast and cervical cancer (5, 10 -12 ) . Indeed, plasma RANTES concentrations have been found to be increased in order of cancer stage (I, II, III, or IV) (5 ) . Furthermore, a large population study found higher plasma concentrations of RANTES in subjects with type 2 diabetes (T2D) and impaired glucose tolerance (IGT) relative to healthy controls (13 ) . Concerning its role in viral disease, RANTES was discovered to be an effective antiviral agent that restricts the entry of CCR5-tropic HIV-1 strains by means of the CCR5 receptor (6 ) . The variant form of RANTES was subsequently found to also inhibit HIV to the same degree but to lack the same binding affinity to the CCR1 receptor. Thus, the impact of RANTES microheterogeneity in biological systems is as important as its quantitative fluctuation.
Commercially available RANTES assays exist widely as ELISAs and appear to be the primary tool for non-variant-specific quantification of plasma RANTES in disease-related studies (5, 14, 15 ) . For reference, 1 such assay has a sensitivity of 2 ng/L, a measuring range of 31.2-2000 ng/L, and intraassay and interassay CVs of 3.6% and 10.3%, respectively (15 ) . Healthy circulating plasma concentrations appear to be around 3 g/L (5 ). The ELISA approach lacks the intrinsic ability to differentiate between wild-type and variant forms of RANTES. The consideration of microheterogeneity, however, may help to explain potential measurement discrepancies between assays. This additional element of multiplexed variant detectability enables a view of the genetic and posttranslational variants of proteins, which may have significant diagnostic value in personalized medicine. Indeed, as McIntosh wrote, "Researchers should be encouraged to evaluate and report as a secondary or even primary analysis the natural variation of the proteome in the clinical biosamples they analyze" (16 ) .
Thus, future quantitative studies of RANTES stand to benefit from a more complete survey of qualitatively different variants of RANTES as they exist in healthy and diseased populations. Toward this end, this report focuses on mapping the structural differences of RANTES found in a variety of diseases. As a result, we provide an alternative qualitative and semiquantitative method for high-throughput populationbased analysis of RANTES that may assist in expanding our understanding of this molecule's complex nature in biological systems.
Materials and Methods

STUDY SUBJECTS AND SAMPLE COLLECTION AND PREPARATION
We prepared and derivatized 1,1Ј-carbonyldiimidazole (CDI)-activated affinity pipette tips with mouse monoclonal antihuman RANTES antibody (R&D Systems), as described for other antibodies (17 ) . For the development of the assay, we used bulk human plasma from a healthy female donor. We acquired 239 additional human samples under institutional review board approval and grouped them into nonoverlapping cohorts as follows: samples from 37 healthy individuals (plasma); 29 healthy individuals (serum); 50 T2D patients (plasma); 25 individuals with congestive heart failure (CHF) and T2D (plasma); 17 individuals with CHF, a history of myocardial infarction (hMI), and T2D (plasma); 25 individuals with CHF and hMI (plasma); 29 individuals with CHF only (plasma); and 27 individuals with cancer (prostate, breast, and colon cancer) (plasma). In all plasma samples, EDTA was used as the anticoagulant. Cohorts were age and sex matched. We pretreated 230 L human plasma with 115 L of a detergent solution containing 4.5% Tween 20, 150 mmol/L octyl-␤-glucopyranoside, 1.5 mol/L ammonium acetate, and concentrated PBS (0.67 mol/L sodium phosphate, 1 mol/L sodium chloride), for a total analytical volume of 345 L. We immobilized negative control mass spectrometric immunoassay (MSIA) tips with monoclonal antihuman C-peptide and insulin antibody (AbD Serotec).
PLASMA MASS SPECTROMETRIC IMMUNOASSAYS
RANTES was extracted with the aid of a Beckman Multimek 96 pipetting robot by repeatedly (500 repetitions) drawing and expelling (back into the analytical volume) 125 L aliquots of the analytical volume through an anti-RANTES affinity pipette. After extraction, we rinsed the pipettes with HBS-P (0.01 mol/L HEPES, 0.15 mol/L NaCl, 0.05% vol/vol surfactant P20, pH 7. 
MASS SPECTROMETRY
We performed MALDI-TOF mass spectrometry (MS) by use of a Bruker Ultraflex III MALDI-TOF instrument operating in the positive-ion, delayed-extraction mode; linear mode with ion source 1 at 25.00 kV, ion source 2 at 23.50 kV, lens at 6.00 kV, 50 ns delayed extraction, deflection signal suppression up to m/z 3000, and 1 GS/s sample rate. Single measurements were acquired, per individual, using 20 000 laser shots signal-averaged to ensure good ion-counting statistics. We externally calibrated the spectra with a mixture of 4 proteins supplied by Bruker (cat. no. 208241), ranging from m/z 5734.52 (insulin [MϩH] ϩ ) to m/z 12360.97 (cytochrome C [MϩH] ϩ ).
DATA ANALYSIS
Individual mass spectra were baseline subtracted (Tophat algorithm) and smoothed (SavitzkyGolay algorithm; width ϭ 0.2 m/z; cycles ϭ 1) before peak integration by use of Bruker Daltonics flexAnalysis 3.0. Peaks representing intact RANTES and RANTES variants were integrated (by use of Intrinsic Bioprobes Inc. Zebra 1.0) and tabulated in a spreadsheet for determination of relative percent abundances.
DUAL EXTRACTION
We extracted RANTES as described above followed by elution into a new sample reservoir. We then extracted this new reservoir as if it were a plasma sample itself, generating a high-purity sample with minimal nonspecific protein binding and an exceptionally clean MALDI-TOF MS spectrum of RANTES. We performed the dual extraction by extracting 20 tips using the normal sample preparation (with the exception of using 1 mL plasma and 500 L detergent solution per sample) followed by MSIA tip elution with 7 L of 33% (vol/vol) acetonitrile and 0.45% (vol/vol) TFA into an Eppendorf tube containing 1 mL HBS-N (0.01 mol/L HEPES and 0.15 mol/L NaCl) and 10 L of 3.9 g/L prealbumin antibody (Dako). The antibody was used as a carrier protein. This enriched sample was subsequently extracted using a new anti-RANTES affinity pipette and eluted as described above. We repeated the process exactly using antihuman insulin antibodyimmobilized tips to serve as a negative control.
Results and Discussion
Fig . 1 shows an MSIA spectrum that is qualitatively representative of those obtained for the individuals investigated in this study (the spectrum is a resized version of that seen in Supplemental Fig. 1B , which accompanies the online version of this article at http:// www.clinchem.org/content/vol56/issue9). Along with intact RANTES, the following variants were identified: 2 N-terminally truncated forms (maroon; II and III), 1 C-terminally truncated form (pink; V), 7 C-and N-terminally truncated forms (blue; IV, VI, VIII, and X-XIII), glycated forms representing intact and (purple; XIV I and XIV II ), oxidized forms (ϩ16 m/z, unlabeled), and 4 glycosylated forms (green; XVI-XIX) ( Fig. 1 and Table 1 ), for a total of at least 19 variants. After fine-tuning to ensure that all MS signals were specific to RANTES via a dual extraction (described below), we tentatively mass-mapped the ions represented in Fig. 1 . Most of these peaks were found in the majority of the samples. With regard to specificity of peak assignments, this type of technique may be viewed as analogous to an ultra-high-resolution Western blot that is performed hundreds of times with consistent results. Notably, peaks I-XIX were not observed in control experiments using blank tips (no antibody immobilized), antihuman C-peptide MSIA tips (single extraction), or antihuman insulin MSIA tips (single and dual extraction). Additional data on antibody specificity is included in the online Supplemental Information.
To ensure accurate mass-mapping assignments, we designed the development of a secondary extraction process (dual extraction) to support the removal of nonspecifically bound proteins and create an exemplar full-scan spectral view of endogenous RANTES microheterogeneity in humans. Typically, 1 MSIA affinity pipette is used to extract a protein from a single plasma sample, which is then rinsed and immediately eluted. Here, we eluted many affinity pipettes from pooled human plasma into a single buffered solution to create a sample with much lower nonspecific protein concentrations and significantly higher RANTES concentration. This consequently created a vastly cleaner MSIA MALDI-TOF MS spectrum with amplified signals corresponding to the weakest endogenous RANTES species present within humans (see online Supplemental Information).
Relative percent abundance (RPA) values of isoforms can be obtained after integrating all mass spectral peak areas (previously determined by a verified protein variant map, e.g., Fig. 1 ), followed by dividing the peak area of each isoform by the summed areas of all isoforms and finally multiplying by 100. To test the reproducibility of this form of semiquantification, we ran a single sample 96 times (i.e., 96 MSIA tips extracted RANTES from 96 samples from the same individual). In this test, RANTES variants , , [4 -68] , and [4 -66] had RPA values (SDs) of 77.82% (0.53%), 20.3% (0.49%), 1.26% (0.07%), and 0.62% (0.05%). The ranges for these variants were observed to be 77.08%-79.60%, 18.67%-20.97%, 1.08%-1.43%, and 0.51%-0.76%, respectively. After establishing a map of RANTES heterogeneity, we scrutinized individual classes of posttranslational modifications in more detail as follows.
TRUNCATION
RANTES was found consistently in a multitude of Nand C-terminally truncated forms (10 individual truncated isoforms were identified). The 2 previously known truncated variants, (II) and [4 -68] (III), are generated by 2 separate regulatory enzymes: DPP-IV and cathepsin G (6, 7 ) . RANTES, as with most chemokines, contains its receptor binding motif at the N-terminus; thus if truncation proceeds, modified chemotactic activity ensues. Therefore, the information content is 2-fold within such a multiplexed assay: indirectly, the enzymatic activity/expression, and directly, the relative abundance of inactive and active protein variants. In this context, this information is in the form of DPP-IV and cathepsin G activity from the abundance of and [4 -68] and each individual's relative ability to induce and/or block signal transduction on target receptors (e.g., full-length RANTES vs DPP-IV-cleaved RANTES). As for the other 8 alternate truncated forms of RANTES found here, the enzymatic activity they indirectly represent remains unknown. More than a decade ago, Proost et al. (18 ) reported on 2 related C-C chemokines, monocyte chemotactic proteins 1 and 2 (MCP-1 and Ϫ2), and the discovery that they exist in several N-and/or C-terminally truncated forms with corresponding modified activity. Notably, Indicated are signals from the ϳ19 major protein isoforms. Isoforms fall into 6 categories: C-and N-terminal truncation, N-terminal truncation only, C-terminal truncation only, multiple truncation possibilities (owing to identical masses), glycosylation, and glycation. Table 1 they observed that N-truncated forms were almost completely devoid of activity but C-terminus-only truncated forms retained full activity. Furthermore, they observed a particular N-truncated form of MCP-2 to act as a natural inhibitor for MCP-2, MCP-1, and RANTES in regard to chemotactic activity. Proost et al. also found an analogous case with RANTES [3-68]-they observed the variant to also act as a natural inhibitor against full-length RANTES and as an effective antagonist of HIV entry into mononuclear cells (19 ) .
We expect these N-terminal-truncated variants to be devoid of activity with increasing lack of receptor specificity the further the variant is truncated inward. Conversely, we expect the C-terminal truncations to have little effect on biological activity. This distinction may be superfluous in this case, however, because most of the C-truncated variants are also N-truncated. A case-in-point example regarding the imperative of acknowledging all truncated isoforms of a protein is the calcium regulatory protein parathyroid hormone (PTH). PTH exists in several embodiments including N and/or C truncations. PTH binds to 2 separate receptors: the classic receptor specific for the amino terminus and an as-of-yet uncloned receptor on the carboxyl Fig. 1 .
terminus, the 2 exerting opposite biological effects in modulating calcium concentrations (20, 21 ) . Interestingly, PTH microheterogeneity has been studied for almost half a century, but the possibility of a C-terminal receptor binding domain was assumed to not exist until very recently. We recently produced a multiplexed assay that can simultaneously distinguish between these active forms (22 ) . Thus, it seems logical that additional assays stand to profit from the ability to unambiguously identify, in a multiplexed manner, an entire full-length protein form. Conversely, as with most "biased" quantification proteomic approaches whereby only 1 or 2 surrogate peptides (resulting from a tryptic digest) are monitored to represent an entire set of protein variants as they exist endogenously, the degree of protein heterogeneity presented here would have been disguised and unacknowledged. This would have been true for all truncated forms if the surrogate peptide were chosen from a midregion. Even if a surrogate peptide were chosen from a terminal region (e.g., to represent ), the assay would still be blind to C-terminal truncation and the possibility of discovering more variants. The MSIA analytical approach allows for the continual analysis of all of these variants.
GLYCOSYLATION AND GLYCATION
We mass-mapped the presence of at least 4 putative O-linked glycosylated variants that appear to exist on both intact and truncated forms of RANTES (observable only on and ; more were not detected corresponding to the other variants likely owing to their already low relative abundance). A ladderlike structure was observed reaching its largest potential at a mass of 8926.9 Da, representing intact RANTES with Deoxyhex 1 HexNAc 3 Hex 2 (see Fig. 1 and Table  1 The glycated signatures of and were detected in the majority of samples. Glycation is common among plasma proteins. To date, however, there do not appear to be any previous reports of RANTES glycation. As we previously demonstrated with vitamin D-binding protein (DBP) (23 ), significant population differences in DBP glycation levels between healthy patients and those with T2D, cardiovascular disease, and cancer were found to be common. Predictably, there is a markedly high increase in glycation in the diabetic and cancer samples studied here. Fig. 2 displays the RANTES spectrum of a non-T2D (cardiovascular disease) patient compared with that of a T2D patient. A Healthy, T2D, CHF (with or without T2D and/or MI), and cancer averages were 7.54%, 48.31%, 44.99%, and 43.12%. T2D, CHF (with or without T2D and/or MI), and cancer were significantly different from the healthy cohort at P Ͻ 0.001. Healthy, T2D, CHF (with or without T2D and/or hMI), and cancer averages were 78.15%, 33.66%, 44.99%, and 43.12%. Healthy was significantly different from the T2D, CHF (with or without T2D and/or hMI), and cancer cohorts at P Ͻ 0.001. glycation peak is observed in the T2D spectrum labeled XIV I , but this peak is absent in the non-T2D spectrum. Several population trends such as this were encountered (Figs. 3-5) .
POPULATION STUDY
Figs. 3-5 represent a population of 239 individuals in different states of health and the diversity of RANTES found therein. The relative abundance for several distinct categories of RANTES heterogeneity is presented. We observed significant RPA differences between all disease cohorts. The subsequent figures compare the relative abundance of and (Fig. 3) , oxidation (Fig. 4), glycation (Fig. 5) , and [4 -66] , , , and (see online Supplemental Information) across all of the disease states. Obvious variation in RANTES profiles begin to emerge in this larger context. For example, in Fig. 3 , a large increase in the RPA of and a large decrease in the RPA of is observed in the majority of the diseased individuals relative to healthy controls. In Fig. 4 , glycation increases significantly in the diseased cohorts, with the T2D individuals unsurprisingly exhibiting the highest relative abundance, having an average value and range of 1.84% (0.84%) and 0.68%-4.06% compared to the healthy cohort value of 0.43% (0.35%) and range of 0.05%-2.55% (the glycation calculation comes from adding together the glycated and ). In Fig. 5 , a markedly higher RPA of oxidized RANTES is observed in the diseased individuals, with the highest increase observed in those with a history of myocardial infarction [average value and range of 9.65% (7.16%) and 0.27%-30.86% compared with the healthy cohort value of 1.42% (0.69%) and 0.17%-3.63%]. Finally, the differences in the relative percent abundances of the lowest-level truncated variants is presented in online Supplemental Fig. 2 , with microdifferences observed between most disease states including the abnormal higher relative abundance of in the CHF and hMI individuals, with an average value and range of 3.05% (7.54%) and 0.02%-36.67% compared with the healthy cohort value of 1.07% (0.58%) and 0.10%-4.26%. Recognizing heterogeneity in this context of multiple diseases presents a unique prospect for diagnosing more than 1 disease, using independent variant markers, from a single protein analysis. It is only after looking at protein phenotypes (e.g., concentration and posttranslational modifications) in Averages of oxidized RANTES in healthy, T2D, CHF and MI, and cancer were 1.23%, 6.12%, 9.65%, and 2.24%. Healthy oxidized RANTES was significantly different from the T2D and hMI cohorts at P Ͻ 0.001 and significantly different from the cancer cohort at P ϭ 0.0013. the context of populations that deviations in protein multiplicity-including changes in population frequency and relative abundance-become clear and thus biomedically applicable (23, 24 ) .
Notably, owing to the ex vivo activity of enzymes in plasma (confirmed by our laboratory by observing the intact form to be processed to ), future population studies may be designed with the use of collection tubes containing enzyme inhibitors. This will guarantee an accurate readout of bioactive (and inactive) RANTES isoforms at the time of collection, which will also be beneficial to establishing interlaboratory standardizations. Regardless, the results illustrate the necessity to acknowledge RANTES diversity and optimistically suggest that it may hold multipurpose clinical utility.
In the span of 2 decades, studies have quickly taken the comprehension of RANTES from a single gene product found in T cells to a molecule that appears to be related with several diseases, expressed in a range of tissues, and acutely regulated via truncation by specific enzymes. In this report, we introduce 16 new forms of the molecule apparent in human plasma in the context of disease populations. The structural variety RANTES exhibits in different disease states should influence the design of future quantitative clinical assays (choice of variant to monitor, internal standard, etc.). The population diversity explored here strongly suggests that RANTES variants should be monitored, independent from one another, to assess RANTES chemokine function and regulation accurately in the context of disease. 
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